Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
50.41
+1.10 (2.23%)
Aug 10, 2026, 10:45 AM EDT - Market open
Boston Scientific Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 20,996 | 20,074 | 16,747 | 14,240 | 12,682 | 11,888 |
Revenue Growth | 13.53% | 19.87% | 17.61% | 12.29% | 6.68% | 19.92% |
Gross Profit Gross Profit Growth | 14,683 | 13,854 | 11,490 | 9,896 | 8,727 | 8,177 |
Operating Income Operating Income Growth | 4,152 | 3,613 | 2,603 | 2,343 | 1,649 | 1,199 |
Net Income Net Income Growth | 3,675 | 2,898 | 1,853 | 1,570 | 642 | 985 |
Earnings Per Share EPS Growth | 2.47 | 1.94 | 1.25 | 1.07 | 0.45 | 0.72 |
EPS Growth | 47.02% | 55.20% | 16.82% | 137.78% | -37.50% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
MedSurg MedSurg Growth | 7,050 | 6,824 | 5,993 | 5,422 | 4,911 | 4,633 |
Cardiovascular Cardiovascular Growth | 13,947 | 13,250 | 10,755 | 8,819 | 7,831 | 7,242 |
Revenue (Total) Revenue (Total) Growth | 20,996 | 20,074 | 16,747 | 14,240 | 12,682 | 11,888 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 539 | 1,965 | 414 | 865 | 928 | 1,925 |
Total Debt Total Debt Growth | 12,624 | 11,436 | 10,746 | 9,102 | 8,935 | 9,065 |
Net Cash (Debt) Net Cash Growth | -12,085 | -9,471 | -10,332 | -8,237 | -8,007 | -7,140 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -8.11 | -6.34 | -6.95 | -5.63 | -5.56 | -4.95 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 4,529 | 4,534 | 3,435 | 2,503 | 1,526 | 1,870 |
Capital Expenditures CapEx Growth | -904 | -876 | -790 | -711 | -588 | -554 |
Free Cash Flow Free Cash Flow Growth | 3,625 | 3,658 | 2,645 | 1,792 | 938 | 1,316 |
Free Cash Flow Growth | 4.02% | 38.30% | 47.60% | 91.05% | -28.72% | 16.25% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 69.93% | 69.01% | 68.61% | 69.49% | 68.81% | 68.78% |
Operating Margin | 19.78% | 18.00% | 15.54% | 16.45% | 13.00% | 10.09% |
Pretax Margin | 18.39% | 16.86% | 13.63% | 13.94% | 9.00% | 9.05% |
Profit Margin | 17.47% | 14.41% | 11.02% | 11.18% | 5.50% | 8.75% |
FCF Margin | 17.27% | 18.22% | 15.79% | 12.58% | 7.40% | 11.07% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.98 | 49.15 | 71.46 | 54.03 | 102.82 | 59.00 |
Forward PE | 14.95 | 28.71 | 33.08 | 26.76 | 24.51 | 23.73 |
P/FCF Ratio | 19.71 | 38.66 | 49.79 | 47.26 | 70.70 | 45.99 |
PS Ratio | 3.40 | 7.04 | 7.86 | 5.95 | 5.23 | 5.09 |